# OnCo record morpho (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/morpho/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "morpho", "NCT02997202" ;
  schema:name "MORPHO"@en ;
  schema:alternateName "BMT CTN 1506"@en, "2215-CL-0304"@en ;
  schema:description "MORPHO asked whether taking the FLT3 blocker gilteritinib for two years after a stem-cell transplant keeps leukaemia from returning; across everyone the benefit fell just short of statistical proof, but in the half of patients whose blood tests still showed traces of leukaemia the drug clearly cut relapses."@en ;
  schema:url <https://onco.cc/trials/morpho/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02997202> ;
  onco:status "mixed" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/aml-flt3/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/gilteritinib/> ;
  onco:companies <https://onco.cc/companies/astellas/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-morpho-gilteritinib-levis-jco-2024/> .